Evaluation of anti-scratch properties of oxatomide and epinastine in mice

European Journal of Pharmacology

Volumn 400, Issue 1, 2000, Pages 73-79

  Inagaki, Naoki ^a   Nagao, Masafumi ^a   Nakamura, Nobuaki ^a   Kawasaki, Hirokazu ^a   Igeta, Katsuhiro ^a   Musoh, Keiichi ^a   Nagai, Hiroichi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anaphylaxis; Cetirizine; Epinastine; Histamine; Histamine H1 receptor; Immunoglobulin E; Mouse; Oxatomide; passive cutaneous; Scratching behavior; Substance P; Terfenadine

Indexed keywords

CETIRIZINE; EPINASTINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; OXATOMIDE; SUBSTANCE P; TERFENADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; MEDIATOR RELEASE; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; PRURITUS; SCRATCHING;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIPRURITICS; CAPILLARY PERMEABILITY; DIBENZAZEPINES; DINITROFLUOROBENZENE; EDEMA; FEMALE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; PASSIVE CUTANEOUS ANAPHYLAXIS; PIPERAZINES; SUBSTANCE P;

EID: 0034648088     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00349-6     Document Type: Article

References (38)

1. Adamus W.S., Oldigs-Kerber J., Lohmann H.F. Antihistamine activity and central effects of WAL 801 CL in man. Eur. J. Clin. Pharmacol. 33:1987;381-385.
2. Adamus W.S., Oldigs-Kerber J., Lohmann H. Pharmacodynamics of the new H1-antagonist 3-amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride in volunteers. Arzneimittelforschung. 37:1987;569-572.
3. Andoh T., Nagasawa T., Satoh M., Kuraishi Y. Substance P inducetion of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J. Pharmacol. Exp. Med. 286:1998;1140-1145.
4. Awouters F., Niemegeers C.J.E., Van den Berk J., Van Nueten J.M., Lenaerts F.M., Borgers M., Schellekens K.H.L., Broeckaert A., De Cree J., Janssen P.A.J. Oxatomide, a new orally active drug which inhibits both the release and the effects of allergic mediators. Experientia. 33:1977;1657-1659.
5. Bergonizi F., Mangili G. Treatment of atopic dermatitis with oxatomide oral suspension (2.5 mg/ml) in infants. Minerva Pediatr. 49:1997;579-587.
6. Bernhard J.D. Clinical aspects of pruritus. Jeffers J.D., Scott E., White J. Dermatology in General Medicine. 1987;78-90 McGraw-Hill, New York, NY.
7. Blockeel J., Leuridan O. Oxatomide effects in follicular conjunctivitis of presumed allergic cause. A double-blind evaluation. Ophthalmologica. 181:1980;133-138.
8. Demaubeuge J., Tennstedt D., Broux R. Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. Dermatologica. 164:1982;386-394.
9. Dupont C., De Maubeuge J., Kotlar W., Lays Y., Masson M. Oxatomide in the treatment of pruritus senilis. A double-blind placebo-controlled trial. Dermatologica. 169:1984;348-353.
10. Duse M., Merlini R., Gardenghi R., Porteri V. Oxatomide in the treatment of atopic dermatitis. Minerva Pediatr. 50:1998;359-365.
11. Eisen H.N., Belman S., Carsten M.E. The reaction of 2,4-dinitrobenzenesulfonic acid with free amino group of proteins. J. Am. Chem. Soc. 75:1953;4583-4585.
12. Fewtrell C.M.S., Foreman J.C., Jordan C.C., Oehme P., Renner H., Stewart J.M. The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J. Physiol. 330:1982;393-411.
13. Greaves M.W. Pruritus. Champion R.H., Burton J.L., Ebling F.J.G. Textbook of Dermatology. vol. 1:1992;527-535 Blackwell, London.
14. Greaves M.W. Pathology and clinical aspects of pruritus. Fitzpatrick T.B., Eisen A.Z., Wolff K., Freedberg I.M., Austen K.F. 4th edn. Dermatology in General Medicine. vol. 1:1993;413-421 McGraw-Hill, New York, NY.
15. Inagaki N., Goto S., Yamasaki M., Nagai H., Koda A. Studies on vascular permeability increasing factors involved in 48-h homologous PCA in the mouse ear. Int. Arch. Allergy Appl. Immunol. 80:1986;285-290.
16. Inagaki N., Goto S., Nagai H., Koda A. Homologous passive cutaneous anaphylaxis in various strains of mice. Int. Arch. Allergy Appl. Immunol. 81:1986;58-62.
17. Inagaki N., Sakurai T., Abe T., Musoh K., Kawasaki H., Tsunematsu M., Nagai H. Characterization of antihistamines using biphasic cutaneous reaction in BALB/c mice. Life Sci. 1998;PL145-PL150.
18. 2 receptors in passive cutaneous anaphylaxis-induced scratching behavior in ICR mice. Eur. J. Pharmacol. 367:1999;361-371.
19. Guideline for animal experimentation. Exp. Anim. 36:1987;285-288.
20. Johnson A., Erdös E.G. Release of histamine from mast cells by vasoactive peptides. Proc. Soc. Exp. Biol. Med. 142:1973;1252-1256.
21. Kamei C., Akagi M., Mio M., Kitazumi K., Izushi K., Masaki S., Tasaka K. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I) elucidation of the mechanism for histamine release inhibition. Immunopharmacol. Immunotoxicol. 14:1992;191-205.
22. Kamei C., Mio M., Kitazumi K., Tsujimoto S., Yoshida T., Adachi Y., Tasaka K. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II) antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. Immunopharmacol. Immunotoxicol. 14:1992;207-218.
23. 2) from rat mast cells and guinea pig lung. Agents Actions. 21:1987;32-37.
24. Kuraishi Y., Nagasawa T., Hayashi K., Satoh M. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur. J. Pharmacol. 275:1995;229-233.
25. Locci F., Del Giacco G.S. Treatment of chronic idiopathic urticaria with topical preparations: controlled study of oxatomide gel versus dechlorpheniramine cream. Drugs Exp. Clin. Res. 17:1991;399-403.
26. Manabe H., Ohmori K., Tomioka H., Yoshida S. Oxatomide inhibits the release of chemical mediators from human lung tissues and from granulocytes. Int. Arch. Allergy Appl. Immunol. 87:1988;91-97.
27. Misawa M., Kanai Y. Effect of the new antiallergic drug epinastine on chemical mediator induced bronchoconstriction in guinea pigs. Arzneimittelforschung. 41:1991;1145-1149.
28. Musoh K., Nakamura N., Sakurai T., Inagaki N., Nagai H. Scratching behavior in mice associated with IgE-mediated allergic cutaneous reaction and its pharmacological characterization. Allergol. Int. 46:1997;117-124.
29. Nagai H., Sakurai T., Inagaki N., Mori H. An immunopharmacological study of the biphasic allergic skin reaction in mice. Biol. Pharm. Bull. 18:1995;239-245.
30. Nijkamp F.P., Folkerts G., Beetens J.R., De Clerck F. Suppression of PAF-induced bronchoconstriction in the guinea pig by oxatomide: mechanism of action. Naunyn-Schmiedeberg's Arch. Pharmacol. 340:1989;111-118.
31. Ohmori K., Ishii H., Kubota T., Shuto K., Nakamizo N. Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea pigs and rats. Arch. Int. Pharmacodyn. Ther. 275:1985;139-150.
32. Origoni M., Garsia S., Sideri M., Pifarotti G., Nicora M. Efficacy of topical oxatomide in women with pruritus vulvae. Drugs Exp. Clin. Res. 16:1990;591-596.
33. Ovary Z. Passive cutaneous anaphylaxis in the mouse. J. Immunol. 81:1958;355-357.
34. Ovary Z. Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction. Prog. Allergy. 5:1958;459-508.
35. Peremans W., Mertens R.L., Morias J., Campaert H. Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. Dermatologica. 162:1981;42-50.
36. Ray M.C., Tharp M.D., Sullivan T.J., Tigelaar R.E. Contact hypersensitivity reactions to dinitrofluorobenzene mediated by monoclonal IgE anti-DNP antibodies. J. Immunol. 131:1983;1096-1102.
37. Sakurai T., Inagaki N., Nagai H. The effect of anti-tumor necrosis factor (TNF)-α monoclonal antibody on allergic cutaneous late phase reaction in mice. Life Sci. 54:1994;PL291-PL295.
38. Tasaka K., Kamei C., Nakamura S. Inhibitory effect of epinastine on bronchoconstriction ninduced by histamine, platelet activating factor and serotonin in guinea pigs and rats. Arzneimittelforschung. 44:1994;327-329.